The phosphodiesterase inhibitors milrinone, levosimendan, clilostazol (PDE3A) and roflumilast (PDE4B) have mixed evidence on whether they are protective or harmful with respect to AF development. The gene discussed is PDE4B; the disease is atrial fibrillation.